Stockreport

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Soc...

Perspective Therapeutics, Inc.  (CATX) 
PDF [212Pb]VMT01 was observed to be safe, and no dose-limiting toxicities were observed at the two doses tested (3.0 and 5.0 mCi)Prolonged progression-free survival and tumo [Read more]